CRNX is no longer listed. Its last trade on record was Sep 2, 2026. The price and figures on this page are from its last trading day and final filings, and are no longer updated.
Last 36 quarters of trend data · Healthcare · Rare Disease Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | 39.31 | 88.06 | 177.66 | 6860.24 | 654.08 | 2162.49 | — | — | 2217.27 | 1321.82 | — | 1220.72 | 247.48 | 80.79 | 347.41 | 576.42 | 557.82 | 83.62 | 298.00 | — |
| — | -94.0% | -95.9% | — | — | -70.5% | +63.6% | — | — | +795.9% | +1536.1% | — | +111.8% | -55.6% | -3.4% | +16.6% | — | — | — | — | — | |
| P/B Ratio | — | 3.31 | 2.95 | 4.41 | 3.66 | 2.30 | 2.49 | 3.53 | 4.91 | 4.26 | 3.87 | 4.43 | 3.08 | 3.85 | 3.09 | 3.11 | 3.01 | 2.54 | 3.46 | 3.87 | 4.17 |
| — | +43.9% | +18.6% | +25.0% | -25.5% | -45.9% | -35.6% | -20.3% | +59.3% | +10.7% | +25.2% | +42.3% | +2.6% | +51.7% | -10.6% | -19.5% | -27.9% | -26.9% | +2.4% | +40.6% | +51.3% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | 99.4% | 98.1% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | 100.0% | 100.0% | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — |
| — | -0.6% | -1.9% | — | — | 0.0% | 0.0% | — | — | 0.0% | 0.0% | — | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — | |
| Operating Margin | — | -527.3% | -1307.8% | -2169.6% | -99710.5% | -12523.0% | -30860.1% | — | — | -20747.6% | -11488.9% | — | -17045.4% | -5363.9% | -1790.9% | -6707.5% | -9487.8% | -9805.2% | -1080.4% | -2865.3% | — |
| — | +95.8% | +95.8% | — | — | +39.6% | -168.6% | — | — | -286.8% | -541.5% | — | -79.7% | +45.3% | -65.8% | -134.1% | — | — | — | — | — | |
| Net Margin | — | -481.1% | -1191.0% | -1993.4% | -90972.7% | -11216.0% | -26807.2% | — | — | -18560.2% | -10457.8% | — | -16606.4% | -5159.8% | -1716.9% | -6345.7% | -9153.9% | -9652.6% | -1105.9% | -2856.6% | — |
| — | +95.7% | +95.6% | — | — | +39.6% | -156.3% | — | — | -259.7% | -509.1% | — | -81.4% | +46.5% | -55.2% | -122.1% | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | -9.8% | -11.3% | -11.9% | -11.6% | -9.5% | -7.5% | -7.5% | -9.2% | -8.7% | -9.5% | -11.1% | -14.3% | -19.1% | -15.4% | -13.5% | -11.4% | -12.3% | -10.9% | -11.7% | -14.1% |
| — | -2.5% | -49.9% | -59.3% | -25.6% | -9.8% | +20.7% | +32.5% | +35.6% | +54.5% | +38.6% | +17.9% | -26.1% | -55.1% | -41.4% | -15.0% | +19.4% | +17.3% | +24.2% | +3.6% | -50.1% | |
| ROA | — | -8.9% | -10.1% | -10.5% | -10.5% | -8.7% | -6.9% | -6.8% | -8.2% | -7.7% | -8.3% | -9.4% | -12.3% | -16.8% | -13.8% | -12.2% | -10.4% | -11.2% | -10.1% | -11.0% | -13.1% |
| — | -1.7% | -45.6% | -55.0% | -27.6% | -12.7% | +16.6% | +27.8% | +33.3% | +53.9% | +39.9% | +22.9% | -18.3% | -49.6% | -36.4% | -11.1% | +20.4% | +18.2% | +23.3% | +2.6% | -48.9% | |
| ROIC | — | -8.3% | -9.8% | -10.3% | -9.8% | -8.1% | -7.2% | -8.5% | -11.5% | -11.2% | -10.3% | -9.5% | -13.1% | -17.3% | -13.6% | -11.7% | -10.0% | -13.3% | -17.2% | -27.3% | -67.7% |
| — | -1.7% | -35.9% | -21.6% | +14.2% | +27.0% | +30.4% | +10.6% | +12.7% | +35.6% | +24.1% | +19.0% | -30.9% | -30.5% | +21.0% | +57.2% | +85.2% | +74.9% | +36.1% | -28.2% | -193.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | 0.04 | 0.04 | 0.05 | 0.05 | 0.04 | 0.04 | 0.04 | 0.06 | 0.06 | 0.06 | 0.10 | 0.10 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 |
| — | -7.1% | -7.8% | +25.3% | -27.3% | -33.6% | -32.5% | -59.3% | -33.8% | +535.8% | +496.1% | +887.0% | +907.5% | +52.0% | +8.1% | +5.0% | -44.9% | -62.4% | -63.3% | -61.0% | -24.1% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | — | 15.57 | 18.60 | 12.32 | 15.12 | 17.80 | 22.53 | 23.04 | 16.38 | 16.09 | 17.72 | 13.07 | 14.23 | 8.73 | 11.60 | 12.45 | 15.41 | 15.94 | 16.20 | 21.55 | 16.40 |
| — | -12.5% | -17.4% | -46.5% | -7.7% | +10.6% | +27.1% | +76.4% | +15.1% | +84.2% | +52.7% | +4.9% | -7.6% | -45.2% | -28.4% | -42.2% | -6.0% | -10.1% | +5.4% | +27.4% | -25.4% | |
| Quick Ratio | — | 15.53 | 18.56 | 12.30 | 15.12 | 17.80 | 22.53 | 23.04 | 16.38 | 16.09 | 17.72 | 13.07 | 14.23 | 8.73 | 11.60 | 12.45 | 15.41 | 15.94 | 16.20 | 21.55 | 16.40 |
| — | -12.8% | -17.6% | -46.6% | -7.7% | +10.6% | +27.1% | +76.4% | +15.1% | +84.2% | +52.7% | +4.9% | -7.6% | -45.2% | -28.4% | -42.2% | -6.0% | -10.1% | +5.4% | +27.4% | -25.4% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 36 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CRNX stock.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Crinetics Pharmaceuticals, Inc.'s business trajectory between earnings reports.